169. Menkes disease Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 6 / Drugs : 6 - (DrugBank : 4) / Drug target genes : 9 - Drug target pathways : 14
Drugs and their primary sponsors and trial info
Copper
Hamamatsu University School of Medicine
2014 - JPRN-UMIN000030626 Japan;
Kobe Unniversitu Graduate School of Medicine
2011 - JPRN-UMIN000005259 Japan;
Copper Histidinate
Cyprium Therapeutics, Inc.
2019 - NCT04074512 -
Copper Histidine
Cyprium Therapeutics, Inc.
2009 Phase 3 NCT00811785 United States;
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1990 Phase 1/Phase 2 NCT00001262 United States;
Diethyldithiocarbamate
Kobe Unniversitu Graduate School of Medicine
2011 - JPRN-UMIN000005259 Japan;
Droxidopa
Stephen G. Kaler, MD
2021 Phase 1/Phase 2 NCT04977388 United States;
Histidine
Hamamatsu University School of Medicine
2014 - JPRN-UMIN000030626 Japan;
Kobe Unniversitu Graduate School of Medicine
2011 - JPRN-UMIN000005259 Japan;
Long Term Follow-Up
Cyprium Therapeutics, Inc.
2019 - NCT04337684 United States;
Hamamatsu University School of Medicine
2014 - JPRN-UMIN000030626 Japan;
Kobe Unniversitu Graduate School of Medicine
2011 - JPRN-UMIN000005259 Japan;
Copper Histidinate
Cyprium Therapeutics, Inc.
2019 - NCT04074512 -
Copper Histidine
Cyprium Therapeutics, Inc.
2009 Phase 3 NCT00811785 United States;
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1990 Phase 1/Phase 2 NCT00001262 United States;
Diethyldithiocarbamate
Kobe Unniversitu Graduate School of Medicine
2011 - JPRN-UMIN000005259 Japan;
Droxidopa
Stephen G. Kaler, MD
2021 Phase 1/Phase 2 NCT04977388 United States;
Histidine
Hamamatsu University School of Medicine
2014 - JPRN-UMIN000030626 Japan;
Kobe Unniversitu Graduate School of Medicine
2011 - JPRN-UMIN000005259 Japan;
Long Term Follow-Up
Cyprium Therapeutics, Inc.
2019 - NCT04337684 United States;